Is BOSTON SCIENTIFIC CORP (BSX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 10.8% / 30% | 1.9% / 30% | 2.8% / 30% | 0.14% / 5% | ✓ HALAL |
| DJIM | 10.8% / 33% | 1.9% / 33% | 2.8% / 33% | 0.14% / 5% | ✓ HALAL |
| MSCI | 26.2% / 33% | 4.5% / 33% | 6.7% / 33% | 0.14% / 5% | ✓ HALAL |
| S&P | 10.8% / 33% | 1.9% / 33% | 2.8% / 33% | 0.14% / 5% | ✓ HALAL |
| FTSE | 26.2% / 33% | 4.5% / 33% | 6.7% / 50% | 0.14% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 68.8% | |
| Operating Margin | 19.7% | |
| Net Margin | 14.4% | |
| Return on Equity (ROE) | 12.4% | |
| Return on Assets (ROA) | 6.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $4.5B |
| Free Cash Flow | $3.4B |
| Total Debt | $11.4B |
| Debt-to-Equity | 48.9 |
| Current Ratio | 1.6 |
| Total Assets | $43.7B |
Price & Trading
| Last Close | $70.17 |
| 50-Day MA | $77.76 |
| 200-Day MA | $94.95 |
| Avg Volume | 14.6M |
| Beta | 0.7 |
|
52-Week Range
$67.56
| |
About BOSTON SCIENTIFIC CORP (BSX)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Purification Calculator
As a halal stock with 0.14% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BOSTON SCIENTIFIC CORP (BSX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BOSTON SCIENTIFIC CORP is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BOSTON SCIENTIFIC CORP's debt ratio?
BOSTON SCIENTIFIC CORP's debt ratio is 10.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 26.2%.
Does BOSTON SCIENTIFIC CORP require dividend purification?
Yes, BOSTON SCIENTIFIC CORP has an impermissible income ratio of 0.14%, which means 0.14% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are BOSTON SCIENTIFIC CORP's key financial metrics?
BOSTON SCIENTIFIC CORP has a market capitalization of $102.8B, trailing P/E ratio of 35.7, and revenue of $20.1B. The company maintains a gross margin of 68.8% and a net margin of 14.4%. Return on equity stands at 12.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.